Castleman's Disease
8
4
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
International Registry for Patients With Castleman Disease
Registry for Adults With Plasma Cell Disorders (PCD's)
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Unlock the Cell: Castleman's Disease Flow Cytometry Study
Castleman Disease Collaborative Network Biobank
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
Dose-escalation Study of Oral CX-4945